Navigation Links
EDAP TMS S.A. Announces $20 Million Placement to Fund US Clinical Studies
Date:10/30/2007

LYON, France, Oct. 30 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP) the global leader in High Intensity Focused Ultrasound treatment of prostate cancer announces that it has entered into a securities purchase agreement with selected United States based qualified institutional buyers ("Investors") pursuant to which the Investors will purchase US $20 million in Unsecured Convertible Debentures convertible into EDAP's ordinary shares which will be delivered in the form of American Depository Receipts ("ADR") at a conversion price of US $6.57.

Proceeds will be used to fund EDAP's already ongoing US Phase II/III clinical study of the Ablatherm-HIFU system in the treatment of localized prostate cancer. The study is treating patients at leading US clinical locations nationwide, with additional centers slated to join. HIFU has been approved for use in the European Union and has been used in over 13,000 cases at centers worldwide; current peer-reviewed clinical studies documenting efficacy and side effects using Ablatherm-HIFU over the past 10 years are available from the company or online at http://www.hifu-planet.com and http://www.edap-tms.com .

The debentures will mature five years from the date of closing bearing 9% interest. EDAP may, provided certain conditions are met, elect to pay all or a portion of interest on the debentures in the form of ADRs. The Investors will also receive warrants to purchase an additional 1,680,000 ADRs at an exercise price of US $6.87, which will expire six years from closing. As part of the transaction, the company has agreed to file a registration statement on Form F-3 with the Securities and Exchange Commission within 30 days following the closing for the purpose of registering for resale the American Depository Shares evidencing the ordinary shares deliverable upon conversion of the debentures, exercise
'/>"/>

SOURCE EDAP TMS S.A.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Diego, CA (PRWEB) October 20, 2014 AttorneyOne.com, ... all the latest information from the FDA on Sit ... on October 10 not to purchase or use Sit and ... Sit and Slim II is promoted as weight loss product ... Sibutramine, removed from the market in 2010 for safety reasons, ...
(Date:10/20/2014)... Succeed is proud to announce that they ... in the Every Body Walk! campaign by Kaiser ... that encourages workers to be more active outside of the ... concluded at the end of September, was a friendly competition ... areas. Participating companies gave their staff pedometers and each ...
(Date:10/20/2014)... Viejo, California (PRWEB) October 20, 2014 Final ... announced the release of the Citrus theme for FCPX ... I would use to describe the Citrus theme” Says Christina ... so easy to look so professional.” , Citrus comes with ... Included with the template are: four transitions for added style, ...
(Date:10/20/2014)... Punzoné , the first line of ultra-premium ... lot to celebrate this month. October marks Italian Heritage Month ... contributions of Americans of Italian heritage and Italians in America. ... shares its favorite Italian cocktails and encourages everyone to enjoy ... if it is only in a glass. , Punzoné ...
(Date:10/19/2014)... October 20, 2014 Hastings and Hastings, ... years of service throughout the greater Phoenix area and ... representation with regard to catastrophic automobile accidents. Statistics have ... country and throughout Arizona. As such, Hastings and Hastings ... legal representation for those who have been injured through ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3
... treatment vs. watchful waiting , MONDAY, July 27 (HealthDay ... who have prostate cancer surgery but leaves unanswered the complicated ... treatment or just watchful waiting. , The study of almost ... removal of a cancerous prostate gland -- between 1987 and ...
... , , WASHINGTON, ... the National Press Club. National Press Club events are open to ... and Newsmakers. Events listed are subject to last-minute changes. Space may ... time and avoid waiting in line, tickets can be paid for ...
... (LRF) is pleased to announce that the 2009 Millennium ... has been awarded to Kai Fu, MD, PhD, Associate ... , Lymphoma, the most common type of ... and non-Hodgkin lymphoma (NHL). According to a 2008 ...
... in never-smokers is poorly understood, but a study led by ... at the National Cancer Institute has identified a molecule believed ... , The findings, published online recently in the Proceedings ... improved therapy for lung cancer in both never-smokers and smokers, ...
... , , PITTSBURGH, July 27 Childhood ... young adults and can lead to premature death in adulthood ... hypertension. In addition to its significant human toll, childhood obesity ... annually. , , To address the continued ...
... A ... the American Society of Andrology,s annual meeting. Study results showed marked improvement in sperm ... the ejaculate. , ... Bellingham, WA (PRWEB) July 23, 2009 -- A clinical study for the male fertility ...
Cached Medicine News:Health News:Men Who Have Prostate Cancer Surgery Do Well 2Health News:Men Who Have Prostate Cancer Surgery Do Well 3Health News:Millennium Pharmaceuticals Inc./Lymphoma Research Foundation funds lymphoma research 2Health News:Molecule plays early role in nonsmoking lung cancer 2Health News:Highmark Provides Pediatricians With Resources to Combat Childhood Obesity 2Health News:Highmark Provides Pediatricians With Resources to Combat Childhood Obesity 3Health News:Male Fertility Supplement Improves Sperm Quality & Motility in Clinical Study 2Health News:Male Fertility Supplement Improves Sperm Quality & Motility in Clinical Study 3Health News:Male Fertility Supplement Improves Sperm Quality & Motility in Clinical Study 4
(Date:10/20/2014)... DIEGO , Oct. 20, 2014  ResMed ... availability of the ResMed Data Exchange program, a ... home medical equipment (HME) and other health care ... timely, secure access to critical patient information. It ... ResMed,s AirView™ and U-Sleep™ patient management platforms with ...
(Date:10/20/2014)... 20, 2014  AnaptysBio, Inc., a leader in ... announced the appointment of Marco Londei , ... lead the preclinical and clinical development of AnaptysBio,s ... pleased to welcome Dr. Londei to AnaptysBio,s executive ... and Chief Executive Officer of AnaptysBio. "Dr. Londei,s ...
(Date:10/20/2014)... Pharmaceutic Labs announces the opening of its ... NY for admixing, compounding, drug shortages and ... the FDA standards for safety and quality, using 21 ... The 10,000 square foot outsourcing facility was ... and quality control. The company will produce sterile and ...
Breaking Medicine Technology:ResMed Launches ResMed Data Exchange 2AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2
... Reduced By an Average of More Than ... N.C., April 02, 2007 /PRNewswire/ --,Adding the ... 24-Hour(TM) Extended-Release Tablets to,Parkinson's patients' existing levodopa ... to continue,their daily activities for a longer ...
... MUNICH, Germany, April 03, 2007 /PRNewswire/ -- ... showing the,improved potency of oritavancin to stop ... common wetting agent (polysorbate 80) and one,study ... in a mouse model of pneumonia. Oritavancin, ...
Cached Medicine Technology:Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 2Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 3Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 4Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 5Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 2Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 3Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 4Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 5Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 6
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: